Skip to main content

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Addition to Russell 2000, 3000 Indexes

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, will be joining the broad-market Russell 3000(R) Index and the small-cap Russell 2000(R) Index at the conclusion of the Russell U.S. Indexes annual reconstitution, which will be effective after the U.S. equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. The annual reconstitution of the Russell indexes identifies the 4,000 largest U.S. stocks as of May 7, 2021; it also ranks them by total market capitalization. Once a company joins the Russell 3000 Index, the membership lasts for one year, until the index conducts its annual reconstitution. Membership in the index also includes automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000 Index along with appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes by evaluating market-capitalization rankings and style attributes. “Inclusion in the Russell indexes reflects the hard work and achievements of the entire Dario team as we work to build the premier digital health and therapeutics company,” said DarioHealth CEO Erez Raphael in the press release. “We look forward to a heightened awareness of our company that inclusion in these widely-followed indexes confers.”

To view the full press release, visit

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.